Jul 7, 2026 05:21AM

Jul 2, 2026 06:46AM

Jun 29, 2026 06:30AM

Jun 26, 2026 04:05PM

May 27, 2026 01:09AM

May 15, 2026 05:03AM

May 14, 2026 07:34AM Larimar Therapeutics, Inc. (LRMR) Tops Q1 EPS by 22c

Mar 19, 2026 02:38PM

Mar 19, 2026 12:57PM

Mar 19, 2026 07:57AM

Mar 3, 2026 09:30AM

Feb 24, 2026 02:23PM

Feb 24, 2026 10:41AM

Jan 12, 2026 04:23PM Larimar Therapeutics reports $136.9 million in cash as of December 31

Jan 5, 2026 06:20AM

Nov 5, 2025 04:14PM

Oct 6, 2025 04:07AM

Oct 3, 2025 04:09AM

Sep 30, 2025 04:05AM

Sep 29, 2025 04:37PM

Sep 29, 2025 02:41PM Leerink on Larimar Therapeutics (LRMR): 'risk/reward profile favorable', PT $25

Sep 29, 2025 07:02AM

Sep 16, 2025 06:51AM

Aug 19, 2025 04:12AM

Aug 15, 2025 04:57AM

Aug 14, 2025 02:19PM

Aug 14, 2025 02:07PM

Aug 14, 2025 01:59PM Larimar Therapeutics (LRMR) PT Lowered to $12 at Citi

Aug 14, 2025 07:24AM

Aug 4, 2025 10:47AM

Jul 29, 2025 04:02PM

Jul 8, 2025 07:02AM

Jun 25, 2025 06:07AM

Jun 23, 2025 01:29PM

Jun 23, 2025 08:27AM Leerink Partners Reiterates Outperform Rating on Larimar Therapeutics (LRMR)

Jun 23, 2025 07:01AM

Apr 23, 2025 04:21AM

Mar 25, 2025 12:52PM

Mar 25, 2025 06:49AM

Mar 25, 2025 04:24AM

Mar 24, 2025 07:03AM

Mar 24, 2025 07:01AM Larimar Therapeutics (LRMR) Provides Nomlabofusp Development Update

Jan 24, 2025 05:18AM

Dec 17, 2024 06:58AM

Dec 17, 2024 06:53AM

Dec 16, 2024 02:38PM

Dec 16, 2024 02:23PM

Dec 16, 2024 01:55PM

Dec 16, 2024 07:02AM Larimar Therapeutics (LRMR) Reports Positive Initial Data from Ongoing Long-term Open Label Extension Study & Progress Across Nomlabofusp Program for Friedreich’s Ataxia

Nov 19, 2024 06:56AM

418,486 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All